According to the Zhitong Finance App, Qingcheng New Pharmaceutical-B (02396.HK) issued an announcement. In view of the “Guidelines”, the board of directors has reviewed and approved the conversion of domestic shares held by participating shareholders to H shares (H shares) and the listing and circulation of such H shares on the main board of the Stock Exchange (full circulation of H shares). After obtaining all relevant approvals (including filing notices from the China Securities Regulatory Commission and approval from the Stock Exchange) and complying with all applicable laws, rules and regulations, 21,681,762 domestic shares will be converted to H shares, and the Company will apply to the Stock Exchange to list and trade such H shares on the main board of the Stock Exchange.

According to the Zhitong Finance App, Qingcheng New Pharmaceutical-B (02396.HK) issued an announcement. In view of the “Guidelines”, the board of directors has reviewed and approved the conversion of domestic shares held by participating shareholders to H shares (H shares) and the listing and circulation of such H shares on the main board of the Stock Exchange (full circulation of H shares). After obtaining all relevant approvals (including filing notices from the China Securities Regulatory Commission and approval from the Stock Exchange) and complying with all applicable laws, rules and regulations, 21,681,762 domestic shares will be converted to H shares, and the Company will apply to the Stock Exchange to list and trade such H shares on the main board of the Stock Exchange.